scholarly journals Systematic Review on Healthcare and Societal Costs of Tinnitus

2021 ◽  
Vol 18 (13) ◽  
pp. 6881
Author(s):  
Ilias Trochidis ◽  
Alessandra Lugo ◽  
Elisa Borroni ◽  
Christopher R. Cederroth ◽  
Rilana Cima ◽  
...  
Keyword(s):  
Systematic Review ◽  
Systematic Reviews ◽  
Economic Burden ◽  
Current Knowledge ◽  
Treatment Options ◽  
Productivity Loss ◽  
Indirect Costs ◽  
The United States ◽  
Economic Evaluations ◽  
Comprehensive Health

Tinnitus disability is a heterogeneous and complex condition, affecting more than 10% and compromising the quality of life of 2% of the population, with multiple contributors, often unknown, and enigmatic pathophysiology. The available treatment options are unsatisfactory, as they can, at best, reduce tinnitus severity, but not eliminate its perception. Given the spread of tinnitus and the lack of a standardized treatment, it is crucial to understand the economic burden of this condition. We conducted a systematic review of the literature on PubMed/MEDLINE, Embase, the Cochrane Database of Systematic Reviews (CDSR) and Google Scholar, in order to identify all the articles published on the economic burden of tinnitus before 1 April 2021 (PROSPERO—International prospective register of systematic reviews—No: CRD42020180438). Out of 273 articles identified through our search strategy, only five articles from studies conducted in the United States of America (USA), the Netherlands and the United Kingdom (UK) provided data on tinnitus’s economic costs. Three studies provided mean annual estimates per patient ranging between EUR 1544 and EUR 3429 for healthcare costs, between EUR 69 and EUR 115 for patient and family costs and between EUR 2565 and EUR 3702 for indirect costs, including productivity loss. The other two studies reported an annual mean cost of EUR 564 per patient for tinnitus-related clinical visits, and total costs of EUR 1388 and EUR 3725 for patients treated with a sound generator and Neuromonics Tinnitus Treatment, respectively. Our comprehensive review shows a gap in the knowledge about the economic burden of tinnitus on healthcare systems, patients and society. The few available studies show considerable expenses due to healthcare and indirect costs, while out-of-pocket costs appear to be less financially burdensome. Comprehensive health economic evaluations are needed to fill the gaps in current knowledge, using a unified method with reliable and standardized tools.

Interventions to alleviate financial toxicity among patients with cancer: A systematic review.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18841-e18841
Author(s):  
Asad Arastu ◽  
Andrew Hamilton ◽  
Emerson Yu-sheng Chen
Keyword(s):  
Systematic Review ◽  
Systematic Reviews ◽  
Financial Burden ◽  
Cost Savings ◽  
Indirect Costs ◽  
The United States ◽  
Financial Toxicity ◽  
Inclusion Criteria ◽  
Related Services ◽  
Assistance Programs

e18841 Background: Financial toxicity (FT) has become a recognized side effect associated with cancer diagnosis and treatment; however, there is little data on what interventions have proven to be effective at mitigating the financial burden patients might face. Methods: A systematic review following the Preferred Reporting Items for Systematic Reviews and Met-Analysis (PRISMA) guidelines was conducted in MEDLINE, Embase, and PsycInfo. Broad terminology to capture FT and all possible interventions was used to identify articles published through June 25, 2020 in MEDLINE and July 31, 2020 in Embase and PsycInfo. We excluded systematic reviews, studies not conducted in the United States, with non-adult participants, or those that did not examine an intervention to directly alleviate FT. Two independent reviewers (AA and EYC) reviewed all abstracts to identify which articles met inclusion criteria. An inductive approach was used to thematically categorize unique intervention strategies. Results: A total of 1126 abstracts were identified from the initial search strategy, and 9 met final inclusion criteria. Across these studies, 12 distinct strategies were reported in 27 unique occurrences. They were mapped into four broad domains: 1) patient assistance programs (PAPs) through pharmaceutical company and/or charity sponsored programs, 2) financial navigators who provide counseling and community resources, 3) direct coverage through free medications or payments, and 4) indirect coverage for related services (e.g. transportation). Direct coverage was most commonly proposed, 15/27 (56%) of interventions, followed by PAPs 5/27 (18%), financial navigators 4/27 (15%), and indirect costs 3/27 (11%). These interventions led to outcomes including: cost savings to patients in 5/9 studies (56%), alleviated fears surrounding cost of treatment in 2/9 (22%), earlier medication fills in 1/9 (11%), and decreased anxiety on a self-reported Likert scale in 1/9 (11%). Conclusions: While potential solutions to FT from cancer care remain unclear, this systematic review demonstrates that particular implemented strategies have lessened patient expenses, improved therapy adherence, or helped patients live better. Additional resources could help equip providers and institutions on how to use existing infrastructure (PAPs) or how to deploy additional workforce to diminish FT.

scholarly journals Direct and Indirect Cost of Obesity: A Systematic Review

2018 ◽  
Vol 10 (9) ◽  
pp. 122 ◽  
Author(s):  
Galih Putri Wulandari ◽  
Susi Ari Kristina
Keyword(s):  
Systematic Review ◽  
Indirect Cost ◽  
Economic Impact ◽  
Healthcare System ◽  
Economic Burden ◽  
Financial Burden ◽  
Productivity Loss ◽  
Indirect Costs ◽  
Developed Countries ◽  
Overweight And Obesity

Obesity is a predictor for various diseases, especially for non-communicable diseases. Obesity impacts large economic burden for patient, healthcare system and the government. This study aims to review the economic impact of obesity worldwide, in terms of direct and indirect costs component of obesity. A systematic review was performed on PubMed, Science Direct and Google Scholar databases during the period 2008-2018. A combination key terms such as “obesity”, “overweight and obesity”, “weight excess”, “economic burden”, “financial burden”, “cost”, “cost of illness”, “direct cost”, “healthcare cost”, “indirect cost”, “productivity loss cost”, and “adult” were used for the search. Relevant original articles published in English and reported both direct and indirect cost of obesity were included in the study. A total of 61 studies were retrieved, then 8 studies were finally selected that met all eligibility criteria which reported both direct and indirect cost of obesity in developing and developed countries. Almost all of studies reported that indirect costs have more proportion than direct costs. The economic burden of obesity was estimated to 0.13-0.22% of Gross Domestic Product (GDP) and 1.5-5.6% of health expenditures. Our review indicated that the direct and indirect cost of obesity has a significant impact to healthcare system and the country. Some health programs and policies are required and should be implemented as soon as possible to reduce the economic impact of obesity.

scholarly journals Mapping evidence on the distribution of the costs associated with cancer of prostate, cervix, and female breast in the sub-Saharan Africa: protocol for a scoping review

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Cebisile Ngcamphalala ◽  
Ellinor Ostensson ◽  
Mbuzeleni Hlongwa ◽  
Themba G. Ginindza
Keyword(s):  
Systematic Reviews ◽  
Scoping Review ◽  
Economic Burden ◽  
Indirect Costs ◽  
Economic Consequences ◽  
Sub Saharan Africa ◽  
Breast Cancers ◽  
Direct And Indirect Costs ◽  
Female Breast ◽  
Sub Saharan

Abstract Background Despite the well-documented information on cancer prevention and management, among noncommunicable diseases (NCDs), globally, cancer continues to be the second leading cause of morbidity and mortality with devastating economic consequences. The burden is disproportionately more among developing countries and the extent of evidence available on the economic consequences (direct and indirect costs) of cancer remains unknown in low-income countries particularly in the sub-Saharan region. Understanding the costs of illness is important to inform decision-making on setting up health care policies and informing economic evaluation of interventions. This study aims to map evidence on the distribution of the economic burden (direct and indirect costs) associated with prevention, diagnosis, and treatment of three predominant cancers: prostate, cervix, and female breast in the sub-Saharan Africa. Methods This scoping review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Reviews (PRISMA-ScR), and will be conducted following Arksey and O’Malley’s framework. We will search PubMed/MEDLINE, Web of Science, CINHAL (via EBSCOhost platform), Science Direct, Cochrane Database of Systematic Reviews, Africa-Wide Information, Google Scholar, and WHO Library. We will perform hand-searching of the reference lists of included studies and other relevant documents. Two reviewers will independently screen all citations, full-text articles, and abstract data. We will include primary studies from all study designs reporting costs associated with prevention, diagnosis and treatment of prostate, cervical, and breast cancers in the sub-Saharan region. Data analysis will involve quantitative (e.g., frequencies) and qualitative (e.g., thematic analysis) methods. A narrative summary of findings will be presented. Discussion This review will map the extent of information available on the economic burden (direct and indirect costs) of prostate, cervical, and breast cancers in the sub-Saharan region. Further guidance for future research in the subject area will be discussed. Systematic review registration Open Science Framework

scholarly journals Assisting With Systematic Reviews Can Be Associated With Job-Related Burnout in Information Professionals

2020 ◽  
Vol 15 (3) ◽  
pp. 181-183
Author(s):  
Kimberly MacKenzie
Keyword(s):  
Systematic Review ◽  
Systematic Reviews ◽  
Rating Scale ◽  
The United States ◽  
Average Score ◽  
Support Tool ◽  
Demographic Groups ◽  
Work Related ◽  
Medical Library ◽  
Information Professionals

Demetres, M. R., Wright, D. N., & DeRosa, A. P. (2020). Burnout among medical and health sciences information professionals who support systematic reviews: An exploratory study. Journal of the Medical Library Association, 108(1), 89–97. https://doi.org/10.5195/jmla.2020.665 Abstract Objective – This study explored reports of burnout among librarians who assist with systematic review preparation. Design – Electronic survey (Copenhagen Burnout Inventory). Setting – The survey was advertised via three email discussion lists based in the United States of America. Subjects – The study surveyed 198 librarians and information specialists who support the systematic review process. Of these, 166 completed the personal burnout scale, 159 completed the work burnout scale, and 151 completed the client burnout scale. Methods – The Copenhagen Burnout Inventory (CBI) is a validated survey that includes three separate scales: personal burnout, work-related burnout, and client-related burnout. The end of the survey addressed demographics, including questions on the respondents’ involvement with systematic reviews. Survey questions use a 0 to 100 rating scale, with 0 indicating Never/To a Low Degree and 100 indicating Always/To a High Degree. The researchers shared the survey to the email discussion lists MEDLIB-L and DOCLINE and advertised it on the Medical Library Association (MLA) News. Survey answers were collected using Qualtrics Survey Software. Once emailed, the survey remained open for one month. Data was coded in Excel and analysis included scoring following the CBI metrics, as well as TukeyHSD and Kruskal-Wallis tests to determine differences in demographic groups. Main Results – Reported burnout levels were significantly lower for those who spend more than 80% of their time helping with systematic reviews compared to those who spend less than 10%. The consistent use of a systematic review support tool was also associated with significantly lower burnout levels. Other comparisons were not significant. The average overall response score for personal burnout was 48.6. The average score for work-related burnout was 46.4 and the average score for client-related burnout was 32.5. Reference librarians reported the highest average total burnout scores (47.1), while research librarians had the lowest (37.7). Conclusion – Consistency, either in time spent dedicated to systematic reviews or in the use of a support tool, was associated with lower levels of burnout among librarians and information specialists. The authors suggest that these results could inform ways of improving burnout among those assisting with systematic reviews.

scholarly journals Análise da Revisão Cochrane: Pregabalina no Tratamento da Dor Crónica Moderada a Grave em Adultos com Fibromialgia. Cochrane Database Syst Rev. 2016;9:CD011790 e 2016;4:CD009002

2018 ◽  
Vol 31 (7-8) ◽  
pp. 376 ◽  
Author(s):  
Guilherme Ferreira-Dos-Santos ◽  
David Cordeiro Sousa ◽  
João Costa ◽  
António Vaz-Carneiro
Keyword(s):  
Systematic Review ◽  
Severe Pain ◽  
Treatment Options ◽  
The United States ◽  
Major Effect ◽  
Cochrane Database ◽  
Noradrenaline Reuptake ◽  
Daily Dose ◽  
Reduction Of Pain

Fibromyalgia can be clinically defined by widespread pain lasting for longer than 3 months with tenderness on palpation in 11 or more of 18 specified tender points. Many people with fibromyalgia are significantly disabled, and experience moderate to severe pain for many years, for which conventional analgesics are usually not effective. For these patients treatment options generally include antidepressants like tricyclic agents, serotonin and noradrenaline reuptake inhibitors, or anticonvulsants like pregabalin or gabapentin. Pregabalin is a drug licensed for the treatment of fibromyalgia in the United States of America, with a mechanism of action similar to gabapentin. This mode of action confers antiepileptic, analgesic, and anxiolytic effects. This Cochrane systematic review included 8 randomized, placebo-controlled trials with low risk of bias, which studied the effect of a daily dose of pregabalin for the treatment of moderate to severe pain in adult patients suffering from fibromyalgia. Of the main results of this systematic review we highlight the major effect that a daily dose of 300 to 600 mg of pregabalin had in the reduction of pain intensity over a follow-up period of 12 to 26 weeks, with tolerable adverse effects, for a minority of people with moderate to severe pain due to fibromyalgia. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice.

scholarly journals A Systematic Review of the Economic Burden of Type 2 Diabetes in Malaysia

2020 ◽  
Vol 17 (16) ◽  
pp. 5723
Author(s):  
Kurubaran Ganasegeran ◽  
Chee Peng Hor ◽  
Mohd Fadzly Amar Jamil ◽  
Hong Chuan Loh ◽  
Juliana Mohd Noor ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Economic Burden ◽  
Data Extraction ◽  
Policy Decision ◽  
Economic Evaluations ◽  
Total Annual Cost ◽  
Adult Type

Diabetes causes significant disabilities, reduced quality of life and mortality that imposes huge economic burden on societies and governments worldwide. Malaysia suffers a high diabetes burden in Asia, but the magnitude of healthcare expenditures documented to aid national health policy decision-making is limited. This systematic review aimed to document the economic burden of diabetes in Malaysia, and identify the factors associated with cost burden and the methods used to evaluate costs. Studies conducted between 2000 and 2019 were retrieved using three international databases (PubMed, Scopus, EMBASE) and one local database (MyCite), as well as manual searches. Peer reviewed research articles in English and Malay on economic evaluations of adult type 2 diabetes conducted in Malaysia were included. The review was registered with PROSPERO (CRD42020151857), reported according to PRISMA and used a quality checklist adapted for cost of illness studies. Data were extracted using a data extraction sheet that included study characteristics, total costs, different costing methods and a scoring system to assess the quality of studies reviewed. The review identified twelve eligible studies that conducted cost evaluations of type 2 diabetes in Malaysia. Variation exists in the costs and methods used in these studies. For direct costs, four studies evaluated costs related to complications and drugs, and two studies were related to outpatient and inpatient costs each. Indirect and intangible costs were estimated in one study. Four studies estimated capital and recurrent costs. The estimated total annual cost of diabetes in Malaysia was approximately USD 600 million. Age, type of hospitals or health provider, length of inpatient stay and frequency of outpatient visits were significantly associated with costs. The most frequent epidemiological approach employed was prevalence-based (n = 10), while cost analysis was the most common costing approach used. The current review offers the first documented evidence on cost estimates of diabetes in Malaysia.

scholarly journals The Economic Burden of Brain Disability in Korea, 2008-2011

2020 ◽  
Vol 57 ◽  
pp. 004695802093639
Author(s):  
Hyun-Jin Kim ◽  
Seung Hee Ho ◽  
Sol Lee ◽  
In-Hwan Oh ◽  
Ju Hee Kim ◽  
...  
Keyword(s):  
Economic Burden ◽  
Health Management ◽  
Productivity Loss ◽  
Indirect Costs ◽  
Premature Death ◽  
Persons With Disabilities ◽  
Rate Of Increase ◽  
Nationally Representative ◽  
All Diseases ◽  
Death Data

This study estimated the economic burden of people with brain disability in Korea during 2008-2011 using nationally representative data and was conducted to use the results as an evidence for determining the resources allocation of people with brain disability. We used a prevalence-based approach to estimate the economic burden, classified by direct costs (medical costs and nonmedical costs) and indirect costs (productivity loss of morbidity and premature death). Data from the National Health Insurance Service, the National Disability Registry, the National survey on persons with disabilities, the Korea National Statistical Office’s records of causes of death, and the Labor Statistics were used to calculate direct and indirect costs. The treated prevalence of brain disability increased from 0.26% (2008) to 0.35% (2011). Total economic burden of brain-related diseases was US$1.88 billion in 2008 and increased to US$2.90 billion in 2011, with a 54% rate of increase. The economic burden of all diseases, which was 1.2 to 1.4 times higher than that of brain-related diseases, accounted for US$2.61 billion in 2008 and US$3.62 billion in 2011, increasing by 39%. Owing to the growing occurrence of brain disability, the annual prevalence and related costs are increasing. Health management programs are necessary to reduce the economic burden of brain disability in Korea.

Sign in / Sign up

Export Citation Format

Share Document